- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| Di | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| Di | OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting | 192 | Newsfile | Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp.... ► Artikel lesen | |
| Di | OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing | 330 | Newsfile | All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds to be used to accelerate OST-HER2 commercial launch preparationsNew... ► Artikel lesen | |
| 27.08. | OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025 | 281 | Newsfile | New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 26.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 26.08. | OS Therapies Terminates Equity Line of Credit | 324 | Newsfile | New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 19.08. | OS Therapies reports Q2 results | 10 | Seeking Alpha | ||
| 19.08. | OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update | 454 | Newsfile | U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission following... ► Artikel lesen | |
| 18.08. | OS Therapies Inc - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 18.08. | Earnings Outlook For OS Therapies | 1 | Benzinga.com | ||
| 15.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025 | 361 | Newsfile | New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 08.08. | OS Therapies files $100M mixed securities shelf | 1 | Seeking Alpha | ||
| 07.08. | OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 192 | Newsfile | 66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046)FDA issues Biologics Licensing Application (BLA) number for OST-HER2... ► Artikel lesen | |
| 07.08. | OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 232 | Newsfile | MHRA seeks to harmonize UK & US regulatory review via Project OrbisEMA Rapporteur Scientific Advice Meeting scheduled for October 2025New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies... ► Artikel lesen | |
| 04.08. | OS Therapies Inc - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.07. | OS Therapies Inc - 8-K, Current Report | 4 | SEC Filings | ||
| 14.07. | OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer | 282 | Newsfile | Cash runway extended through 2026, beyond September 30, 2026 sunset date for rare pediatric priority review voucher (PRV) program Additional funding allows Company to advance strategic alternatives... ► Artikel lesen | |
| 10.07. | OS Therapies Provides Clinical & Global Regulatory Updates | 266 | Newsfile | End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma programScientific Advice Meetings confirmed with global regulators in major... ► Artikel lesen | |
| 03.07. | OS Therapies Shares Climb As FDA Grants End Of Phase 2 Meeting For OST-HER2 Program In Osteosarcoma | 1 | RTTNews |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 44,600 | -1,33 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| IMMUNIC | 0,690 | +1,17 % | B.Riley lowers Immunic stock price target to $4 as catalyst-rich period approaches | ||
| PHIO PHARMACEUTICALS | 2,120 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,000 | -2,39 % | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update | Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,710 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| PROTALIX BIOTHERAPEUTICS | 1,410 | 0,00 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:30 a.m. EDT
CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,750 | -1,27 % | Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) | ||
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Strategische Impfstoff-Entwicklungen und Finanzierungspläne vorgestellt | ||
| SCILEX | 18,640 | 0,00 % | Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc. | Denali's registration statement on Form S-4 declared effective by the Securities and Exchange CommissionExtraordinary general meeting of Denali Capital Acquisition Corp. shareholders to approve the... ► Artikel lesen | |
| MEIRAGTX | 6,400 | +1,59 % | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results | - Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX)... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 1,080 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Presents Interim Data from MyClimb Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 | ||
| INVIVYD | 1,040 | 0,00 % | Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") | New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA® (pemivibart) against XFG Centers for Disease Control data and wastewater surveillance data indicate XFG... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 4,320 | 0,00 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease | LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics prices upsized $250M stock offering | ||
| AVIDITY BIOSCIENCES | 47,230 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |
OS THERAPIES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,230 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.